TAVRA Biosciences
PrivateLast Round
Seed Round
Mar 31, 2026
Est. Valuation
$660.25M
Total Funding Raised
$156M
Company Overview
TAVRA Biosciences is a biotechnology company that supplies cGMP-manufactured stem cell biologic products to licensed physicians for clinical use in orthopedics, sports medicine, and pain management.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
TAVRA Biosciences Comparables
Compare TAVRA Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BridgeBio | 79% | |
| Taiho Pharmaceutical Co., Ltd. | 78% | |
| Eli Lilly and Company | 77% |
For institutional investors. Book with your work email.
TAVRA Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Mar 31, 2026 | ||||
| Private Placement | Feb 6, 2024 | ||||
| IPO | Sep 17, 2021 | ||||
| Series B | Mar 31, 2021 | ||||
| Series A | Jan 10, 2020 |
For institutional investors. Book with your work email.
TAVRA Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series B |
| RA Capital Management | Series B, Private Placement, Series A |
| Boxer Capital | Series B, Private Placement, Series A |
| OrbiMed | Private Placement |
| 5AM Ventures | Private Placement |
| Logos Capital | Series B |
| Canaan Partners | Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 31, 2026
$300K raised in Seed Round.
- Feb 6, 2024
$200M raised in a private placement round.
For institutional investors. Book with your work email.
TAVRA Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about TAVRA Biosciences's valuation, stock price, and market status.
Is TAVRA Biosciences a public or private company?
TAVRA Biosciences is a private company.
What is the current stock price of TAVRA Biosciences?
TAVRA Biosciences is a private company, so its shares have no public market price. Caplight tracks TAVRA Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is TAVRA Biosciences worth (valuation)?
TAVRA Biosciences's valuation is estimated at $660.3M based on funding round data.
Can I buy TAVRA Biosciences stock?
TAVRA Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was TAVRA Biosciences's last funding round?
TAVRA Biosciences's most recent funding round was Seed Round on March 31, 2026.
Who are the main investors in TAVRA Biosciences?
Key investors in TAVRA Biosciences include RA Capital Management, Boxer Capital, Canaan Partners, Nextech Invest, TD Cowen.
Will TAVRA Biosciences IPO soon?
No public IPO plans have been announced for TAVRA Biosciences.
How can I track TAVRA Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in TAVRA Biosciences's shares on secondary markets.